Taken together, IL-1β represents a model in which adipokines may be indirectly employed as target molecules for the treatment of obesity-related and inflammation-induced insulin resistance comorbidities as well as for some autoimmune diseases. Here, IL1B is linked to obesity due to melanocortin 4 receptor deficiency.